InterMune Inc

InterMune — Investor Presentation (June 2014)

40 slides from InterMune's investor presentation, Jun 4, 2014

  1. Slide 1: Corporate Overview June 2014

    Corporate Overview June 2014 Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation contains forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that, without limitation, statements in this presentation regarding InterMune's plans and ex

  3. Slide 3: Our Strategy: Maximize the Value of Esbriet and Grow Beyond Esbriet and IPF

    Our Strategy: Maximize the Value of Esbriet (Pirfenidone) and Grow Beyond Esbriet and IPF A B C New formulations Phase 4 ISTs Registries Key launch and commercialization activities Vision: Leader in Specialty Fibrotic Diseases New indications Pirfenidone Analog LPA-1 Biomarkers Business Development

  4. Slide 4: Commercializing Esbriet in IPF Europe/Canada

    Commercializing Esbriet ® in IPF Europe/Canada

  5. Slide 5: Our EU Commercialization Strategy: Focus First on Top 5

    Our EU Commercialization Strategy: Focus First on Top 15 Esbriet is now available for prescription for 85% of the IPF patients in the Top 15 EU countries Focus First on Top 5 Countries: Germany, France, Italy, UK, Spain Population of 314 million ~ 70-75% of EU market value Esbriet has launched in 4

  6. Slide 6: Success: Consecutive Quarters of Growth Esbriet Revenue – EU and Canada

    Success: 10 Consecutive Quarters of Growth Esbriet Revenue – EU and Canada • Anticipate Q over Q growth over time • Growth rate expected to moderate due to fewer country launches and completion of NPP patient conversions to commercial customers and the larger revenue base 2.7 4.9 5.5 7.5 8.2 10.5 14

  7. Slide 7: Commercializing Esbriet in IPF USA: ASCEND Phase 3 Study

    Commercializing Esbriet in IPF USA ASCEND Phase 3 Study for U.S. Registration

  8. Slide 8: A Phase 3 Trial of Pirfenidone in Patients with IPF (NEJM)

    the NEW ENGLAND JOURNAL of MEDICINE A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis wh Sat MD, Rover Susan MLD) Supe D0. In fe pase 3 wih feng, mela ry. ced ‘ese progress eased yt dine noel Yeap OME ot ‘tala in pts ith pati pa os te hi alin ‘od tn wn soca Ne oh oni te e

  9. Slide 9: ASCEND Study Efficacy Results Presented at ATS May 2014

    ASCEND Study Efficacy Results Presented at ATS May 2014

  10. Slide 10: Primary Efficacy Analysis: Significant Between-group Difference in Rank ANCOVA

    Primary Efficacy Analysis: Treatment with Pirfenidone Resulted in a Significant Between-group Difference in the Rank ANCOVA Analysis (P<0.000001) Week Pirfenidone (N=278) Placebo (N=277) Absolute Difference 2.5% 7.9% 12.3% 15.3% Relative Difference 54.0% 58.0% 57.8% 47.9% Rank ANCOVA p-value <0.0000

  11. Slide 11: Primary Efficacy Analysis: %FVC Change at Week 52

    Primary Efficacy Analysis: %FVC Change at Week 52 * Rank ANCOVA p-value <0.000001 Pirfenidone (N=278) Placebo (N=277) Pirfenidone (N=278) Placebo (N=277) Relative Difference 132.5%* 22.7 9.7 16.5 31.8 Relative Difference 47.9%*

  12. Slide 12: Supportive Analysis: Treatment Group Difference of 193 mL at Week 52

    Supportive Analysis of the Primary Endpoint: Treatment Group Difference of 193 mL at Week 52 — a 45% Relative Reduction in the Mean Change in FVC Absolute difference, mL 59.6 111.0 116.7 192.8 Relative difference 62.5% 54.9% 43.9% 45.1% Rank ANCOVA P-value <0.000001 <0.000001 0.000002 <0.000001 Plac

  13. Slide 13: Supportive Analysis: Annual Rate of FVC Decline at Week 52

    Supportive Analysis of the Primary Endpoint: Annual Rate of FVC Decline at Week 52 Favored Pirfenidone (Linear Slope Analysis) * Linear slope analysis: Mixed model with linear time effect adjusted for age, height, and sex -300 -250 -200 -150 -100 -50 Pirfenidone (N=278) Placebo (N=277) Absolute Diff

  14. Slide 14: 6-Minute Walk Distance: Significant Between-group Difference

    6-Minute Walk Distance: Significant Between-group Difference in the Change from Baseline to Week 52 Absolute Difference 3.7% 10.9% 10.9% 9.8% Relative Difference 24.1% 39.7% 31.8% 27.5% Rank ANCOVA p-value* 0.401 0.119 0.041 0.036 * Tested for multiple comparisons using the Hochberg procedure Week P

  15. Slide 15: Progression-free Survival: Risk of Progression or Death Reduced by 43%

    Progression-free Survival*: Pirfenidone Reduced the Risk of Disease Progression or Death by 43% * Time to death or disease progression (confirmed 10% decline in FVC or confirmed m decline in 6MWD) † Log-rank test Pirfenidone Placebo Patients at Risk: Week Placebo (N=277) Pirfenidone (N=278) P<0.001

  16. Slide 16: Slide 16

  17. Slide 17: Pre-Specified Pooled All-cause Mortality Analysis (Week 52)

    Pre-Specified Pooled All-cause Mortality Analysis (Week 52): Treatment Group Curves Diverge Early and Continue Separating Throughout the Study Period Pirfenidone Placebo Patients at Risk, n: * Cox proportional hazards model † Log-rank test Month Placebo (N=624) Pirfenidone (N=623) HR 0.52 (95% CI 0.

  18. Slide 18: Slide 18

  19. Slide 19: UCSD SOBQ Score: No Significant Difference in Dyspnea at Week 52

    UCSD SOBQ Score: No Significant Difference in Dyspnea Between Groups at Week 52 Absolute Difference 2.6% 6.2% 3.4% 7.0% Relative Difference 20.9% 23.9% 10.9% 19.3% Rank ANCOVA p-value 0.145 0.172 0.258 0.158

  20. Slide 20: ASCEND Treatment-emergent Adverse Events

    ASCEND Study: Treatment-emergent Adverse Events*: Fewer Serious Adverse Events and Fewer Deaths in the Pirfenidone Group. Less than 4% More Patients in the Pirfenidone Group Discontinued Treatment Due to an AE Patients, n (%) Pirfenidone (N=278) Placebo (N=277) Any adverse event 277 (99.6) 272 (98.2

  21. Slide 21: ASCEND: GI and Skin-related Events More Common in Pirfenidone Group

    ASCEND Study: GI and Skin-related Events Were More Common in the Pirfenidone Group Patients (%) Pirfenidone (N=278) Placebo (N=277) Cough 25.2 29.6 Nausea 36.0 13.4 Headache 25.9 23.1 Diarrhea 22.3 21.7 Upper Respiratory Tract Infection 21.9 20.2 Fatigue 20.9 17.3 Rash 28.1 8.7 Dyspnea 14.7 17.7 Diz

  22. Slide 22: ASCEND: Cough, Dyspnea, and IPF Worsening More Frequent in Placebo Group

    ASCEND Study: Cough, Dyspnea, and IPF Worsening Occurred with a Greater Frequency in the Placebo Group Patients (%) Pirfenidone (N=278) Placebo (N=277) Cough 25.2 29.6 Nausea 36.0 13.4 Headache 25.9 23.1 Diarrhea 22.3 21.7 Upper Respiratory Tract Infection 21.9 20.2 Fatigue 20.9 17.3 Rash 28.1 8.7 D

  23. Slide 23: Pooled Population (N=1247): Summary of Efficacy Outcomes at One Year

    Pooled Population (N=1247): Summary of Efficacy Outcomes at One Year Decline in %FVC =10% or death Decline in 6MWD =50 m or death Progression-free survival Decline in UCSD SOBQ =20 points or death All-cause mortality Treatment-emergent all-cause mortality IPF-related mortality Treatment-emergent IPF

  24. Slide 24: ASCEND Study: Summary

    ASCEND Study: Summary Treatment with pirfenidone for 52 weeks significantly reduced disease progression, as measured by Changes in % predicted FVC (p<0.000001) Changes in 6-minute walk distance (p=0.036) Progression-free survival (p<0.001) Treatment with pirfenidone reduced all-cause mortality and t

  25. Slide 25: Commercialize Esbriet in IPF: USA — Next Steps

    Commercialize Esbriet in IPF: USA — Next Steps NDA resubmitted: May 23, 2014 Class 2 NDA resubmission; six-month FDA review Build the commercial infrastructure* • 100-140 will be field-based (sales force, managers, managed care, support) • 25-35 will be HQ-based Majority hired in H2 2014; gated to r

  26. Slide 26: U.S. IPF Prevalence

    U.S. IPF Prevalence U.S. IPF Population Mild to Moderate (30,000-50,000) Severe (~20,000) ~70k diagnosed prevalent IPF patients in the U.S. ~30-50k IPF patients with mild to moderate impairment EU and Canada label indication is for mild to moderate patients All Phase 3 trials to support U.S. approva

  27. Slide 27: Expected U.S. Payor Mix for Esbriet

    Expected U.S. Payor Mix for Esbriet Source: SHA Prescription and Medical Claims for IPF Diagnosed Patients (516.31) between Oct 2010 – Oct 2013 IPF patients are identified as patients with at least one IPF diagnosis between Oct 2010 and Oct 2013 The payor mix shown above is based on Rx claims for th

  28. Slide 28: Factors Impacting Time to Reimbursement and Revenue Uptake in First 9 Months

    Many Factors Impact the Time to Product Reimbursement and Revenue Uptake During the First 9 Months of Launch 1 2 3 4 5 6 7 8 9 10 11 12 Launch Month Market Access (6 - 9 months) • Minimum months to convene P&T committee • Lack of familiarity with IPF adds to review time • Denials, Prior-Authorizatio

  29. Slide 29: Successful U.S. Orphan/Specialty Drug Launches

    Successful U.S. Orphan/Specialty Drug Launches Revlimid® Gleevec® Namenda® Tracleer® Peak Revenue ($MM) $2430 $1939 $1537 $774 Annualized First Year ($MM) $299 $151 $45 $51 First Year as % of Peak 12% 8% 3% 7% Source: Evaluate Pharma. Successful analog products have achieved a range of 3% to 12% of

  30. Slide 30: Successful Launches: Quarterly Net Revenue as Percent of First Year Sales

    Successful U.S. Orphan/Specialty Drug Launches: Quarterly Net Revenue as a Percent of First Year Sales Source: EvaluatePharma, L.E.K. analysis • On average, about one third of the first 12 months’ revenues was realized in the first two quarters Revlimid® Tracleer® Gleevec® Q3 Q2 Q1 Q4 • The fourth q

  31. Slide 31: Esbriet Price: Benchmark Products in the U.S. Have a Broad Range of Prices

    Esbriet Price: Benchmark Products in the U.S. have a Broad Range of Prices ($000’s/year)* * Wholesale Acquisition Cost (WAC). Source: AnalySource (12/17/13) (PAH) (PAH) Oral or inhaled administration Infusion or injection administration (mCRPC) (cystic fibrosis) (severe epilepsy) (multiple sclerosis

  32. Slide 32: Esbriet IP – Extends Patent Protection Beyond Orphan Drug Status

    Esbriet IP – Extends Patent Protection up to 10 Years Beyond Orphan Drug Status Comprehensive patent estate provides protection beyond Orphan Drug exclusivity; 20-year patent terms range from 2026 to 2033 21 patents issued and allowed in U.S., 7 in EU InterMune’s IP supported by four pillars: 1. Pat

  33. Slide 33: Esbriet IP and Regulatory Exclusivity Protection in the U.S.

    Esbriet IP and Regulatory Exclusivity Protection in the U.S. Exclusivity Protections • Patents covering different aspects of the product and its use provide stronger protection overall a “picket fence” • In order to launch, generics must successfully challenge or avoid all of InterMune’s patents • M

  34. Slide 34: Expand Esbriet in IPF

    Expand Esbriet in IPF Program Description Rationale Status PANORAMA Study Esbriet +/- NAC NAC is used widely in EU and USA Opportunistic – if PANTHER were positive Launched Q3 2013 Under Review post negative PANTHER Results (May 2014) New Esbriet Formulations Development of optimized formulation Enh

  35. Slide 35: Grow Beyond Esbriet and Beyond IPF

    PASSPORT/Country Registries U.S. Esbriet LAUNCH Q1 New Formulation Studies LOTUSS Phase 2b (SSc-ILD) PANORAMA (Esbriet +/- NAC) External Opportunities Under Evaluation IND Development Phase 1 Drug Discovery Drug Discovery IND Development Grow Beyond Esbriet and Beyond IPF Esbriet Esbriet Life Cycle

  36. Slide 36: Our Small Molecule Anti-Fibrotic Research Programs

    Our Small Molecule Anti-Fibrotic Research Programs Lead Compound Mechanism Route of Administration Dosing Schedule Differentiation Status IP protection (Composition of Matter) Pirfenidone Analogs (ITMN-30162, ITMN-14440) Pirfenidone scaffold, Anti-TGF-b Oral BID to QD Improved tolerability, efficacy

  37. Slide 37: Financial Overview

    Financial Overview Cash and cash equivalents (3/31/14): $606.4M Convertible debt: $18.4M due 2015: 5.00% coupon, $18.88 conversion price $120.75M due 2017: 2.50% coupon, $12.87 conversion price $155M due 2018: 2.50% coupon, $31.80 conversion price 2014 YTD Guidance Revenue $70.3M $30.3M $130 - $140M

  38. Slide 38: Summary

    Summary IPF is an attractive orphan market Large orphan, huge unmet medical need, strong pricing and small marketing structure leading to large opportunity with high operating margins Esbriet (pirfenidone) has first-mover advantage and continues its momentum in Europe and Canada U.S. launch of pirfe

  39. Slide 39: InterMune – Leader in IPF

    ee INTERMUNE’ Leader in IPF

  40. Slide 40: InterMune – Leader in IPF

    ee INTERMUNE’ Leader in IPF

InterMune — Investor Presentation (June 2014) on 6ix